Indegene Limited (INDGN) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹614.5 (-1.25% day change)
Key ratios
- P/E ratio
- 36.75
- P/B ratio
- 3.32
- ROE (%)
- 12.78
- ROCE (%)
- 13.94
- Debt/Equity
- 0.05
- Dividend yield (%)
- 0.46
- Market cap (₹ Cr)
- 14,808.4
Forensic checks
Piotroski F-Score: 3/9 · Altman Z-Score: 9.66 · Beneish M-Score: -2.07
InvestSights quality score
74.2/100 — Above Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q2 FY27)
AI summary: The central signal is that Indegene’s growth investments are beginning to translate into broader client expansion, larger contracts and improving productivity, but the expected margin payoff remains weighted toward Q4 FY27. Q2 revenue reached ₹11,223 million, with growth spread across top-five, top-20 and newer accounts, while the client base expanded to 107. Tectonic’s…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.